Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 8 |
| List of Tables | 7 | 3 |
| List of Figures | 10 | 2 |
| Neurometabolic Disorders Market to 2017 - Introduction | 12 | 2 |
| GBI Research Report Guidance | 13 | 1 |
| Neurometabolic Disorders Market to 2017 - Global Market Overview | 14 | 6 |
| Introduction | 14 | 1 |
| Market Revenue | 14 | 2 |
| Annual Cost of Therapy | 16 | 1 |
| Treatment Usage Pattern | 17 | 1 |
| Diseased Population | 18 | 1 |
| Treatment Seeking Population | 18 | 1 |
| Diagnosed Population | 18 | 1 |
| Prescription Population | 19 | 1 |
| Neurometabolic Disorders Market to 2017 - Geographical Landscape | 20 | 15 |
| The US | 21 | 1 |
| Revenue | 21 | 2 |
| Annual Cost of Therapy | 23 | 1 |
| Treatment Usage Pattern | 24 | 1 |
| Diseased Population | 25 | 1 |
| Treatment Seeking Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 26 | 1 |
| Top Five Countries of Europe | 26 | 1 |
| Revenue | 26 | 2 |
| Annual Cost of Therapy | 28 | 1 |
| Treatment Usage Pattern | 29 | 1 |
| Diseased Population | 30 | 1 |
| Treatment Seeking Population | 30 | 1 |
| Diagnosed Population | 30 | 1 |
| Prescription Population | 30 | 1 |
| Japan | 31 | 1 |
| Revenue | 31 | 1 |
| Annual Cost of Therapy | 32 | 1 |
| Treatment Usage Pattern | 33 | 1 |
| Diseased Population | 34 | 1 |
| Treatment Seeking Population | 34 | 1 |
| Diagnosed Population | 34 | 1 |
| Prescription Population | 34 | 1 |
| Neurometabolic Disorders Market to 2017 - Therapeutic Landscape | 35 | 47 |
| Neurometabolic Disorders Market to 2017 - Gaucher s Disease | 35 | 1 |
| Introduction | 35 | 1 |
| Revenue | 36 | 2 |
| Revenue by Geography | 38 | 2 |
| Annual Cost of Therapy | 40 | 1 |
| Treatment Usage Pattern | 41 | 1 |
| Diseased Population | 41 | 1 |
| Treatment Seeking Population | 42 | 1 |
| Diagnosed Population | 42 | 1 |
| Prescription Population | 42 | 1 |
| Treatment Algorithm | 43 | 1 |
| Gaucher s Type 1 Disease Therapeutics Market Drivers | 44 | 1 |
| Promising Pipeline Molecules in Late stage of Development | 44 | 1 |
| Increase in Awareness Levels among Gaucher s Patients | 44 | 1 |
| Gaucher s Type 1 Disease Therapeutics Market Restraints | 45 | 1 |
| Low Diagnosis Rate | 45 | 1 |
| High Treatment Cost | 45 | 1 |
| Neurometabolic Disorders Market to 2017 - Niemann-Pick Type C Disease | 45 | 1 |
| Introduction | 45 | 2 |
| Revenue | 47 | 1 |
| Revenue by Geography | 48 | 2 |
| Annual Cost of Therapy | 50 | 1 |
| Treatment Usage Pattern | 51 | 1 |
| Diseased Population | 51 | 1 |
| Treatment Seeking Population | 52 | 1 |
| Diagnosed Population | 52 | 1 |
| Prescription Population | 52 | 1 |
| Treatment Algorithm | 53 | 1 |
| Niemann-Pick Type C Market Drivers | 54 | 1 |
| Increase in Disease Awareness | 54 | 1 |
| Increase in Drug Uptake in Europe and Other Countries | 55 | 1 |
| Niemann-Pick Type C Market Restraints | 55 | 1 |
| Lack of Approval and Reimbursement of Zavesca in the US and Japan | 55 | 1 |
| Misdiagnosis | 55 | 1 |
| Neurometabolic Disorders Market to 2017 - Pompe Disease | 56 | 1 |
| Introduction | 56 | 1 |
| Revenue | 56 | 2 |
| Revenue by Geography | 58 | 2 |
| Annual Cost of Therapy | 60 | 1 |
| Treatment Usage Pattern | 61 | 1 |
| Diseased Population | 62 | 1 |
| Treatment Seeking Population | 62 | 1 |
| Diagnosed Population | 62 | 1 |
| Prescription Population | 63 | 1 |
| Treatment Algorithm | 63 | 1 |
| Pompe Disease Therapeutics Market Drivers | 64 | 1 |
| Approval of Lumizyme and Strong Growth in Sales of Marketed Drugs | 64 | 1 |
| Increase in Disease Awareness and Increased Support for Medical Research | 64 | 1 |
| Pompe Disease Therapeutics Market Restraints | 65 | 1 |
| Poor Diagnosis and Treatment Seeking Rate | 65 | 1 |
| High Cost of Therapy | 65 | 1 |
| Neurometabolic Disorders Market to 2017 - Fabry Disease | 65 | 1 |
| Introduction | 65 | 1 |
| Revenue | 65 | 2 |
| Revenue by Geography | 67 | 2 |
| Annual Cost of Therapy | 69 | 1 |
| Treatment Usage Pattern | 70 | 1 |
| Diseased Population | 71 | 1 |
| Treatment Seeking Population | 71 | 1 |
| Diagnosed Population | 71 | 1 |
| Prescription Population | 71 | 1 |
| Fabry Disease Therapeutics Market Drivers | 72 | 1 |
| Promising Late Stage Pipeline Molecules (Pharmacological Chaperones) for the Treatment of Fabry Disease | 72 | 1 |
| Increase in Awareness Levels of Disease Progression and Etiology | 72 | 1 |
| Fabry Disease Therapeutics Market Restraints | 73 | 1 |
| Misdiagnosis of Fabry Disease | 73 | 1 |
| High Annual Cost of the Treatment | 73 | 1 |
| Neurometabolic Disorders Market to 2017 - Mucopolysaccharidosis VI | 73 | 1 |
| Introduction | 73 | 1 |
| Revenue | 74 | 1 |
| Revenue by Geography | 75 | 1 |
| Annual Cost of Therapy | 76 | 1 |
| Treatment Usage Pattern | 77 | 1 |
| Diseased Population | 78 | 1 |
| Treatment Seeking Population | 78 | 1 |
| Diagnosed Population | 78 | 1 |
| Prescription Population | 78 | 1 |
| Treatment Algorithm | 79 | 1 |
| Mucopolysaccharidosis VI Therapeutics Market Drivers | 80 | 1 |
| Strong Performance by Existing Branded Drugs | 80 | 1 |
| Increase in Disease Awareness | 80 | 1 |
| Mucopolysaccharidosis VI Therapeutics Market Restraints | 81 | 1 |
| Poor Diagnosis Rate | 81 | 1 |
| Neurometabolic Disorders Market to 2017 - Major Marketed Products | 82 | 10 |
| Gaucher s Disease | 82 | 1 |
| Cerezyme | 82 | 1 |
| Overview | 82 | 1 |
| Mechanism of Action | 82 | 1 |
| Efficacy Details | 82 | 1 |
| Safety Issues | 83 | 1 |
| VPRIV | 83 | 1 |
| Overview | 83 | 1 |
| Mechanism of Action | 84 | 1 |
| Efficacy Details | 84 | 1 |
| Safety Issues | 84 | 1 |
| Gaucher s Disease and Niemann-Pick Type C | 85 | 1 |
| Zavesca | 85 | 1 |
| Overview | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| Efficacy Details | 85 | 1 |
| Safety Issues | 86 | 1 |
| Pompe Disease | 86 | 1 |
| Myozyme/Lumizyme | 86 | 1 |
| Overview | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| Efficacy Details | 87 | 1 |
| Safety Issues | 88 | 1 |
| Fabry Disease | 88 | 1 |
| Fabrazyme | 88 | 1 |
| Overview | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| Efficacy Details | 88 | 1 |
| Safety Issues | 89 | 1 |
| Replagal | 89 | 1 |
| Overview | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| Efficacy Details | 89 | 1 |
| Safety Issues | 90 | 1 |
| Mucopolysaccharidosis VI | 91 | 1 |
| Naglazyme | 91 | 1 |
| Overview | 91 | 1 |
| Mechanism of Action | 91 | 1 |
| Efficacy Details | 91 | 1 |
| Safety Issues | 91 | 1 |
| Neurometabolic Disorders Market to 2017 - Product Pipeline Analysis | 92 | 11 |
| Gaucher s Disease - Research and Development Pipeline | 94 | 1 |
| Overview | 94 | 1 |
| Pipeline by Phase | 94 | 1 |
| Niemann-Pick Type C: Research and Development Pipeline | 95 | 1 |
| Overview | 95 | 1 |
| Pipeline by Phase | 95 | 1 |
| Pompe Disease: Research and Development Pipeline | 96 | 1 |
| Overview | 96 | 1 |
| Pipeline by Phase | 96 | 1 |
| Fabry Disease: Research and Development Pipeline | 97 | 1 |
| Overview | 97 | 1 |
| Pipeline by Phase | 97 | 1 |
| Most Promising Molecules | 98 | 1 |
| Uplyso | 98 | 1 |
| Overview | 98 | 1 |
| Mechanism of Action | 98 | 1 |
| Research and Development Brief | 98 | 1 |
| Discovery/Preclinical Trial Details | 99 | 1 |
| Genz-112638 | 99 | 1 |
| Overview | 99 | 1 |
| Mechanism of Action | 99 | 1 |
| Phase III Trials | 100 | 1 |
| Phase II Trials | 100 | 1 |
| Amigal | 101 | 1 |
| Overview | 101 | 1 |
| Mechanism of Action | 101 | 1 |
| Phase III Trials | 101 | 1 |
| Phase II Trials | 101 | 1 |
| Phase I Trials | 102 | 1 |
| Other Developmental Activities | 102 | 1 |
| Neurometabolic Disorders Market to 2017- Competitive Landscape | 103 | 25 |
| Overview | 103 | 2 |
| Company Profiles | 105 | 1 |
| Genzyme Corporation | 105 | 1 |
| Overview | 105 | 1 |
| SWOT Analysis | 105 | 1 |
| Deals | 106 | 7 |
| Shire | 113 | 1 |
| Overview | 113 | 1 |
| SWOT Analysis | 113 | 1 |
| Deals | 114 | 6 |
| BioMarin Pharmaceutical Inc. | 120 | 1 |
| Overview | 120 | 1 |
| SWOT Analysis | 121 | 1 |
| Deals | 122 | 2 |
| Actelion | 124 | 1 |
| Overview | 124 | 1 |
| SWOT Analysis | 125 | 1 |
| Deals | 126 | 2 |
| Neurometabolic Disorders Market to 2017 - Strategic Consolidations | 128 | 7 |
| Overview | 128 | 1 |
| Sanofi S.A. Completes Acquisition of Genzyme | 129 | 1 |
| Deal Summary | 129 | 1 |
| Deal Rationale | 129 | 1 |
| Pfizer Enters into a Licensing Agreement with Protalix Biotherapeutics | 130 | 1 |
| GlaxoSmithKline Enters into Licensing Agreement with Amicus Therapeutics for Amigal | 130 | 1 |
| Amicus Therapeutics Terminates Licensing Agreement with Shire | 131 | 1 |
| Deals by Geography | 131 | 1 |
| Deals by Licensing Type | 132 | 1 |
| Deals by Value | 133 | 1 |
| Deals by Phase | 134 | 1 |
| NDA Filed | 134 | 1 |
| Taliglucerase alpha | 134 | 1 |
| Phase III | 134 | 1 |
| Amigal | 134 | 1 |
| Neurometabolic Disorders Market to 2017 - Appendix | 135 | 8 |
| Market Definitions | 135 | 1 |
| Abbreviations | 135 | 1 |
| Research Methodology | 136 | 2 |
| Coverage | 136 | 1 |
| Secondary Research | 137 | 1 |
| Primary Research | 137 | 1 |
| Therapeutic Landscape | 138 | 3 |
| Epidemiology-based Forecasting | 138 | 2 |
| Market Size by Geography | 140 | 1 |
| Geographical Landscape | 141 | 1 |
| Pipeline Analysis | 141 | 1 |
| Competitive Landscape | 141 | 1 |
| Expert Panel Validation | 141 | 1 |
| Contact Us | 141 | 1 |
| Disclaimer | 141 | 1 |
| Sources | 142 | 1 |